David Hutton


Betamethasone 0.2% gets positive marks in Phase II trial for treatment of post-cataract surgery pain, inflammation

The investigational therapy met all primary endpoints of absence of inflammation at both Day 8 and Day 15 for the treatment of pain and inflammation following cataract surgery.

Enrollment completed for first Phase 3 study of perfluorohexyloctane

Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.

Artificial cornea restores patient’s vision

A device developed by an Israeli startup was implanted in the eye of a patient, enabling him to recognize his family and read words.

As COVID-19 focuses attention on vaccine, medication shortages loom

January 14, 2021

Amid ramped up production of vaccines, CARES Act gives FDA power to head off potential drug shortfalls. Prevent Blindness is urging the FDA to use its authority to ensure TED treatment drug supply isn’t interrupted.